We have located links that may give you full text access.
[A simple and rapid routine preparation of no-carrier added meta-I-123- and I-131-iodobenzylguanidine (I-123-MIBG and I-131-MIBG) for clinical nuclear medicine applications].
AIM: Low specific activity meta-iodobenzylguanidine (I-123/I-131-MIBG) is currently used in the assessment of abnormalities in the myocardial neuroadrenergic function as well as in the management of neuroendocrine tumors. In recent studies an enhanced cardiac and tumor uptake were reported by the use of high specific activity radiopharmazeuticals, suggesting a potential clinical benefit of no-carrier-added (n.c.a.) I-123/I-131-MIBG. In this paper we describe a simple and improved preparation of I-123-MIBG and I-131-MIBG for routine clinical application, feasible in any nuclear medicine department.
METHODS: N.c.a I-123-MIBG and n.c.a. I-131-MIBG were prepared by Cu(I)-assisted [I-123/I-131]iodo-debromination at 170-175 degrees C with 86 +/- 6% and 80 +/- 10% radiochemical yield respectively and high specific activity (> or = 4.3 TBq/mumol and > or = 0.21 TBq/mumol), starting from meta-bromobenzylguanidine (MBBG). The total time of synthesis including the HPLC purification and the preparation of the injectable solution was less than 60 min.
RESULTS: Neither rechromatography by HPLC nor TLC gave any indication of disintegration products in the injection solution up to 8 h after preparation. Moreover, biological testings confirmed that the buffered and sterile-filtered n.c.a. I-123-MIBG and n.c.a. I-131-MIBG solutions are isotonic, sterile and apyrogenic and thus suitable as injectable solutions for clinical use.
CONCLUSION: High specific activity I-123-MIBG and I-131-MIBG could now be prepared by a simple one-step reaction giving rise to high radiochemical yields and high purity for a widespread clinical applications. Therefore, this encourages clinical validations on a large scale to answer the question of whether n.c.a. I-123-MIBG and I-131-MIBG could play an important role in the assessment of the myocardial sympathetic nervous dysfunction as well as in the diagnosis and therapy of neuroendocrine tumors.
METHODS: N.c.a I-123-MIBG and n.c.a. I-131-MIBG were prepared by Cu(I)-assisted [I-123/I-131]iodo-debromination at 170-175 degrees C with 86 +/- 6% and 80 +/- 10% radiochemical yield respectively and high specific activity (> or = 4.3 TBq/mumol and > or = 0.21 TBq/mumol), starting from meta-bromobenzylguanidine (MBBG). The total time of synthesis including the HPLC purification and the preparation of the injectable solution was less than 60 min.
RESULTS: Neither rechromatography by HPLC nor TLC gave any indication of disintegration products in the injection solution up to 8 h after preparation. Moreover, biological testings confirmed that the buffered and sterile-filtered n.c.a. I-123-MIBG and n.c.a. I-131-MIBG solutions are isotonic, sterile and apyrogenic and thus suitable as injectable solutions for clinical use.
CONCLUSION: High specific activity I-123-MIBG and I-131-MIBG could now be prepared by a simple one-step reaction giving rise to high radiochemical yields and high purity for a widespread clinical applications. Therefore, this encourages clinical validations on a large scale to answer the question of whether n.c.a. I-123-MIBG and I-131-MIBG could play an important role in the assessment of the myocardial sympathetic nervous dysfunction as well as in the diagnosis and therapy of neuroendocrine tumors.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Diagnosis and Management of Cardiac Sarcoidosis: A Scientific Statement From the American Heart Association.Circulation 2024 April 19
Essential thrombocythaemia: A contemporary approach with new drugs on the horizon.British Journal of Haematology 2024 April 9
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app